These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 24062525)

  • 1. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.
    Kang Y; Hu W; Ivan C; Dalton HJ; Miyake T; Pecot CV; Zand B; Liu T; Huang J; Jennings NB; Rupaimoole R; Taylor M; Pradeep S; Wu SY; Lu C; Wen Y; Huang J; Liu J; Sood AK
    J Natl Cancer Inst; 2013 Oct; 105(19):1485-95. PubMed ID: 24062525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel facts about FAK: new connections to drug resistance?
    Annunziata CM; Kohn EC
    J Natl Cancer Inst; 2013 Oct; 105(19):1430-1. PubMed ID: 24062526
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
    Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
    Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
    Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.
    Halder J; Landen CN; Lutgendorf SK; Li Y; Jennings NB; Fan D; Nelkin GM; Schmandt R; Schaller MD; Sood AK
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8829-36. PubMed ID: 16361572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
    McNamara B; Demirkiran C; Hartwich TMP; Bellone S; Manavella D; Mutlu L; Greenman M; Zipponi M; Yang-Hartwich Y; Yang K; Ratner E; Schwartz PE; Coma S; Pachter JA; Santin AD
    Gynecol Oncol; 2024 Apr; 183():133-140. PubMed ID: 38493021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
    Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.
    Tancioni I; Uryu S; Sulzmaier FJ; Shah NR; Lawson C; Miller NL; Jean C; Chen XL; Ward KK; Schlaepfer DD
    Mol Cancer Ther; 2014 Aug; 13(8):2050-61. PubMed ID: 24899686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.
    Levy A; Alhazzani K; Dondapati P; Alaseem A; Cheema K; Thallapureddy K; Kaur P; Alobid S; Rathinavelu A
    Curr Cancer Drug Targets; 2019; 19(3):179-188. PubMed ID: 29984656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
    Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
    BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
    Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
    Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.
    Demirkiran C; Greenman M; Bellone S; McNamara B; Hartwich TMP; Manavella D; Mutlu L; Zipponi M; Yang-Hartwich Y; Yang K; Ratner E; Schwartz PE; Coma S; Pachter J; Santin AD
    Gynecol Oncol; 2024 Aug; 187():12-20. PubMed ID: 38703673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
    Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
    Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.
    Zhang S; Lu Z; Mao W; Ahmed AA; Yang H; Zhou J; Jennings N; Rodriguez-Aguayo C; Lopez-Berestein G; Miranda R; Qiao W; Baladandayuthapani V; Li Z; Sood AK; Liu J; Le XF; Bast RC
    PLoS One; 2015; 10(7):e0131833. PubMed ID: 26146988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
    Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
    J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.
    Haemmerle M; Bottsford-Miller J; Pradeep S; Taylor ML; Choi HJ; Hansen JM; Dalton HJ; Stone RL; Cho MS; Nick AM; Nagaraja AS; Gutschner T; Gharpure KM; Mangala LS; Rupaimoole R; Han HD; Zand B; Armaiz-Pena GN; Wu SY; Pecot CV; Burns AR; Lopez-Berestein G; Afshar-Kharghan V; Sood AK
    J Clin Invest; 2016 May; 126(5):1885-96. PubMed ID: 27064283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.
    Yang YI; Lee KT; Park HJ; Kim TJ; Choi YS; Shih IeM; Choi JH
    Carcinogenesis; 2012 Dec; 33(12):2488-98. PubMed ID: 23027625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
    Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
    Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.